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                           General introduction
p-Opioid receptors
   Pharmacological studies using the peptide anq alkaloid opioid receptor ligands have
identified several types of opioid receptors, including pt, 6 and K '-3). In the year 1992,
a 6-opioid receptor (DOR) was first cloned by two independent groups, Evans et al. 4)
and,Kieffer et al. 5). Following the cloning of the DOR, the pt-opioid receptor (MOR)
and K-opioid receptor (KOR) have been cloned in the past several years 6'9). The
studies on cDNA clone encoding structurally related receptor with amino acid have
suggested the similarity of these three receptor genes as high as 659o 'O"i). The
cloning of these opioid receptor types revealed that they are members of the G-protein-
coupled receptor (GPCR) superfamily. Opioid receptors are coupled to pertussis
toxin-sensitive Gi/o protein, which are linked functionally to inhibition of adenylyl
cyclase activity, activation of receptor-operated K' currents, and suppression of
voltage-gated Ca2' currents i2"`). Recently, it has been demonstrated that opioid
receptors may be coupled to other second messenger systems, including activation of
the mitogen-activated protein kinase (MAPK) and the phospholipase C (PLC)/ inositol
(1,4,5)-triphQsphate (IP,)/protein kinase C (PKC)-mediated cascade, through the Py
subunits of their G proteins "i'). Actions of MOR agonists have been subdivided into
pti- and pt2-opioid receptor mechanisms, based upon the effect of the selective pti-opioid
receptor antagonist naloxonazine '8). It has long been considered that pi-opioid
receptors mediate antinociception supraspinally, whereas pt2-opioid receptors are
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responsible for spinal antinociception. However, no report on the identification of pi
and pt2 subtypes at the molecular level has been provided so far.
Splice variant-dependent MOR subtypes
   Many GPCR genes contain introns, which introduce the possibility of variants due
to alternative splicing. Variations in gene-product splicing occur at the Ievel of
processing of heteronuclear-RNAs in the cell nucleus. A growing body of evidence
suggests that alternative splicing with 14 exons results in several spliced variants for
the cloned MOR '9'20). Several splice variant-dependent MOR subtypes that are
different in length and amino acid composition 'only at the intracellular carboxyl
terminus have been identified. Among the isolated variants, MOR-1 that has exon 1,
2, 3 and 4, and MOR-IB that contains an alternatively spliced exon 5 instead of the
original exon 4 2i'22). It was reported that the expression of MOR-IB mRNA can be
observed in.many brain areas. The highest concentrations of MOR-IB mRNA are
detected in the frontal cortex and striatum, and the lowest concentrations are found in
the olfactory bulb and the cerebellum 2i). Following agonist stimulation, MOR-IB
shows an accelerated cycle of receptor endocytosis and reactivation, which in turn
promotes a greater resistance to agonist-induced desensitization than MOR-1 2'-as).
   In term of MOR-IC, the 12 amino acids encoded by exon 4 in MOR-1 are replaced
by 52 amino acids derived from the combination of the new exons 7, 8 and 9, which
are conserved exons among other two'variants'
 MOR-IE and -IF 24). Previous
immunohistochemical study demonstrated tha•t intense MOR-IC-immunoreactivity
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(IR) is observed in the hypothalamic nuclei and lateral septum, whereas moderate
MOR-1-IR is presented in these regions. Conversely, MOR-1-IR js found abundantly
in the striatum, whereas no expression of MOR-IC is observed in the same region 2S.
It has been proposed that MOR-IC shows the rapid receptor desensitization, whereas
littIe or no jntemalizatjon is caused following prolonged exposure to MOR agonists 26).
Considering these findings, it can be speculated that individual splice variants derived
from the same MOR gene partially differ in their functional roles in the expression of
MOR agonist-induced pharmacological actions.
The use of opioids to treat chronic pain
   The primary afferent nociceptor is generally the initial structure involved in
nociceptive processes. The primary afferent fibers associated with transmission
nociceptive signals to the substantia gelatinosa in the dorsal horn can be grouped into
two main categories: small myelinated (A-6) and unmyelinated (C) sensory afferent
fibers 27'28). Second-order neurons ascend the spinal cord to terminate in many
supraspinal structures throughout the brain stem, thalamus and cortex. In the
thalamus, it is well-known that these systems are divided into two main groups such as
ventrobasal complex and intralaminar nuclei.29) Former including the ventral
posterolateral nuclei and ventral posteromedial nuclei, is involved in the sensory
discriminative component of pain and further projects to the somatosensory cortex.29-3')
Latter including the• central medial nuclei and parafascicular nucleus, amygdala and
hippocampus, is associated with the affective motivational aspects of pain and projects
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to the cingulate cortex. Chronic peripheral tissue inflammation often produces a state
of neuropathic pain characterized by hyperalgesia (an exaggerated pain in response to
painful stimuli) and allodynia (a pain evoked by normally innocuous stimuli). The
development of neuropathic pain following peripheral tissue inflammation depends
both on an increase in'the sensitivity of these first synapses at the insite of
inflammation and on an increase in the excitability of neurons in the central nervous
system (CNS) 32'3`). Several animal models of neuropathic pain following peripheral
tissue inflammation have been created for the investigation of mechanisms underlying
the induction of neuropathic pain 3536). Complete Freund's adjuvant (CFA),
carrageenan and formalin have been well documented to produce the state of
inflammatory pain hypersensitivity in rodents following intraplantar injection.
   Opioids have been used to treat patients with chronic pain. Recent ctinical trials
suggest that oxycodone, morphine and levorphanol can improve chronic pain such as
diabetic peripheral neuropathy and postherpetic neuralgia 3D. In addition, early
pharmacological studies have demonstrated that the microinjection of a typical MOR
agonist morphine or endogenous MOR agonist endomorphin-1 into ventrolateral
orbha1 cortex dramatically suppressed the state of inflammatory pain hypersensitivity
in rodents i2). On the contrary, several lines of clinical evidence have demonstrated
that neuropathic pain is panicularly difficult to treat, as it is only partially relieved by
high doses of MOR agonists. These clinical experience are supported by findings that
the antinociceptive effects by either subcutaneous (s.c.) or intrathecal (i.t.) treatment
with morphine was attenuated in rodents with sciatic nerve ligation `2•'3•38).
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Furthermore, Narita et al. 39) showed previously that the phosphorylation of MOR,
which leads to uncoupling with G-proteins, was clearly increased in the superficial
laminae of the L5 lumbar spinal dorsal horn of the mice with chronic pain. Under
these conditions, the morphine-induced antinociceptive effect was significantly
suppressed in mice with chronic pain. Thus, the utility of opioids for neuropathic pain
remains controversial. It is likely that the reason for the limited application of MOR
agonists in the clinical environment is related to a poor understanding the analgesic
properties of these MOR agonists under the pain-like state.
MOR agonists, morphine and fentanyl
   According to the World Health Organization (WHO) guidelines for patients with
moderate or severe cancer pain, morphine has been a "gold standard" for treatment of
moderate to severe cancer pain. The i.t. administration of morphine has been the
standard therapy to control long-term intractable pain. However, the use of morphine
for the treatment of cancer pain is sometimes accompanied by side effects such as
emesis, vomiting, sedation, papiilary constriction, euphoria, constipation and
drowsiness rc'"). Quality of Iife has been shown to be significantly reduced in patients
who experience morphine-induced side effects. In 1959, fentanyl, the
anilidopiperidine class of MOR agonist, was reported as a potent synthetic analgesic
with a Iower propensity to produce these undesirable effects in the clinical setting `2).
Fentanyl is used for opioid rotation in the clinic and exhibits 50-1oo times more potent
analgesic activity and short duration of its action as compared to that of morphine.
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The low molecular weight and lipid solubility of fentanyl make it possible for delivery
via the transdermal therapeutic system. The transdermal therapeutic fentanyl-system
allows for a continued and sustained titratable amount of fentanyl to be delivered
without the inconvenience of the typical administration of other analgesics for 24 hr.
However,•it has been considered that the analgesic tolerance is the adverse effect in the
pain management of pain with fentanyl `3). The understanding of mechanism
underlying the opioid side effects and the establishment of the strategy to prevent and
manage them are essential skills for pain management.
Opioid tolerance and receptor turnover
   The development of chronic tolerance is characteristic of all opioids with agonist
activity, regardless of the receptor type with which they interact. Tolerance to opioids
first becomes evident as a shortening of the duration of drug action and a diminution of
the peak effects. The rate at which tolerance develops depends on the pattern of use
and the characteristics of the opioids used. Significant tolerance only develops when
there is• a continuous drug action.
   Tolerance can be described as an adaptation of a biological systern to the repeated
effects of a drug and defined as a loss of potency of a drug after its repeated
administration. The processes underlying opioid tolerance involve complex
compensatory changes in many opioid and non-opioid neuronal circuits. One major
mechanism controlling GPCR responsiveness is the activation-dependent regulation of
receptors, called homologous desensitization op'45). Other mechanisms also contribute
                                    6
to intrinsic regulation of GPCR signaling. These mechanisms include receptor
activation-independent regulation, called heterologous desensitization, which results
from regulating and altering the signaling efficiency of downstream effectors `6'`D.
Among homologous adaptiye processes, the receptor desensitization, internaljzation
and trafficking appears to play key role in the development of opioid tolerance. A
number of studies demonstrated that long-term or repeated treatment with MOR
agonists leads to the rapid receptor desensitization followed by internalization of
MORs. A growing body of evidence suggests that the phosphorylation of MOR at
diverse sites of its intracellular domain by G protein-coupled receptor kinase (GRK) or
second messenger-regulated protein kinases such as PKC and Ca2'/calmodulin-
dependent protein kinase II (CaMKII) has been shown to trigger the internalization of
phosphorylated MOR from the celi surface to the cytosoi `8). These processes are
thought to be an important step toward receptor desensitization. Among diverse
serine/threonine residues of intracellular domain of MOR, phosphorylation of serine
(Ser) 375 in the mouse MOR is essential for its internalization. After phosphorylation
of Ser/threonine (Thr) residues of the C-terminus, MORs are internalized via clathrin--
coated pits into early endosomes and subsequently dephosphorylated by intracellular
protein phosphatases. The dephosphorylated MORs might be either recycled through
sorting endosomes back to the plasma membrane or transported to the lysosomes for
degradation. It has been considered that opioid tolerance is, in part, the end results of
a coordinated balance between processes governing desensitization and resensitization
of MORs. However, the mechanisms underlying the development of tolerance to
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MOR agonists have not been fully understood. Most previous studies conceming
molecular events in opioid tolerance have been performed using the excessive dose of
MOR agonists or several cell lines including the non-neural cell model. It seems
likely that these previous experimental models are not necessarily correspond to actual
situation of opioid tolerance observed in the clinic. Therefore, in order to further
clarify properties and molecular mechanisms of analgesic tolerance, I should
investigate the utility of repeated treatment with MOR agonists at optimal doses for the
relief of pain associated with physiological change in endogenous MOR system and its
related downstream signaling machinery.
CXBK recombinant inbred mice
   To date, a number of studies concerning differences of the pharmacological
property between morphine and fentanyl have been undertaken. Previous
electrophysiological and biochemical studies have indicated that fentanyl and its analog
sufentanil, but not morphine, reversibly suppressed sodium inward currents through the
neuronal voltage-gated sodium channels `9). Furthermore, it is well established that
fentanyl induces internalization of MORs, whereas morphine does not promote
detectable internalization of MORs in cultured cells. Thus, the individual
pharmacological character of morphine or fentanyl is clearly different.
   CXBK mice are recombinant inbred mice derived from a cross between the
C57BL/6J and BALBIcJ strains. so'5') Previous studies suggested that CXBK mice had a
partial deficiency of MOR proteins and the level of MOR mRNA in the brain of CXBK
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mice as compared to their progenitor mice and other outbred strains 52). On the other
hand, the densities of DOR and KOR appear to be relevantly unaffected by the
deficiency of MORs in CXBK mice. The sequence of the coding region (1197 bases)
of MOR mRNA of CXBK mice is identical to that of C57BL/6J mice. Within the 726
bases of 3'-untranslated region (UTR) and 241 bases of 5'-UTR of the MOR gene, a
C/A polymorphism at 5LUTR is the only difference between CXBK (C nucleotide) and
C57BL/6J (A nucleotide) mice 53). It has been well known that these genetic variation
in UTR regions are known to affect the expression level of either the corresponding
mRNA or protein without the influence upon its function 5`). The inheritance of MOR
gene of CXBK mice was well correlated with its behavioral pharmacologic properties,
which is less sensitivity to MOR agonists. Mizoguchi et al. 5S demonstrated that
endogenous MOR agonists endomorphin-1 and endomorphin-2 increase guanosine-5'-
o-(3-[35S]thio)triphosphate ([35S]GTPyS) binding to the pons!medulla membranes from
C57BL/6J mice in a concentration-dependent manner. However, the increases of
[35SIGTPyS binding induced by either endomorphin-1 or endomorphin-2 in CXBK
mice were significantly much lower than those in C57BL/6J mice. It is therefore
worthwhile to use CXBK mice to further investigate the pharmacological profiles of
MOR agonists such as morphine and fentanyl.
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                             Aim and Scope
   The aim of the present study was to investigate the molecular mechanism of the
development of tolerance to anti-hyperalgesic effects between chronic treatment with
morphine and fentanyl under the pain-like state. Therefore, behavioral, neurochemical
and biochemical experiments were conducted in the present study.
The specific aims of the proposed research are:
In Chapter 1:
   The aim of the present study was to investigate whether repeated in vivo
administration of morphine or fentanyl could cause the development of tolerance to the
morphine- or fentanyl-induced anti-hyperalgesic effect under the long-lasting pain-like
state induced by intraplantar administration of CFA in mice. Additionally, I evaluated
the effect of repeated administration of morphine and fentanyl on the regulatory process
of MOR trafficking, which is responsible for receptor phosphorylation, internalization
and recycling pathways, following CFA injection in mice. ,
In Chapter 2:
   I investigated whether CXBK recombinant inbred mice, which are known to have a
partial deficiency of MOR, could be deficient in a putative splice variant-dependent
MOR subtype MOR-IB. Furthermore, I evaluated the functional role of supraspinal
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MOR-IB in the endogenous MOR agonist endomorphin-1-induced antinociceptive
effects.
In Chapter 3:
   To clarify the antinociceptive properties of morphine and fentanyl in the mouse
supraspinal and spinal cord, I investigated the effects of pretreatment with MOR, DOR
and KOR antagonist, P-funaltrexamine (6-FNA), naltrindole methanesulfonate (NTI)
and nor-binaltorphimine hydrochloride (nor-BNI), respectively, on the antinociceptive
effects induced by morphine or fentanyl using the mouse tail-flick test. In addition, I
compared 509o effective dose (EDso) values for antinociceptive effects between
morphine and fentanyl at peripheral, spinal and supraspinal site, respectively, in ICR
mice. Finally, I investigated the specific involvement of MOR subtypes at either the
spinal or supraspinal site with analgesic properties of morphine and fentanyl using
CXBK mice.
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Ethics
   The present study was conducted in accordance with the Guiding Principles for the
Care and Use of Laboratory Animals, as adopted by the Committee on Animal Research
of Hoshi University, which is accredited by the Ministry of Education, Culture, Sports,
Science and Technology of Japan. Every effort was made to minimize the numbers
and any suffering of animals used in the following experiments. Animals were used
only once in the present study.
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Chapter 1
Differences in tolerance to anti-hyperalgesic effects between
treatment with morphine and fentanyl under the pain-like state
chronic
13
Introduction
   Tolerance can be described as an adaptation of a biological system to the repeated
effects of a drug and defined as a loss of potency of a drug after its repeated
administration. The processes underlying antinociceptive tolerance involve complex
compensatory changes in many opioid and non-opioid neuronal circuits. Among
homologous adaptive processes, the receptor desensitization, internalization and
trafficking appear to play the key role in the development of opioid tolerance i5"7). A
number of studies demonstrated that long-term or repeated treatment with MOR
agonists leads to the rapid receptor desensitization followed by internalization of MORs.
The initial process of these events is that the phosphorylation of intracellular domains of
MOR by GRK or second messenger-regulated protein kinases such as PKC and
CaMKII "i7). After phosphorylation of SerlThr residues of the C-terminus, MORs are
internalized via clathrin-coated pits into early endosomes and subsequently
dephosphorylated by intracellular protein phosphatases. The dephosphorylated MORs
might be either recycled through sorting endosomes back to the plasma membrane or
transported to the lysosomes for degradation. It has been considered that
antinociceptive tolerance is, in part, the end results of a coordinated balance between
processes governing desensitization and resensitization of MORs. Previous
electrophysiological and biochemical studies have indicated that endogenous opioid
peptides and certain nonpeptide agonists such as etorphine and fentanyl induce either
functional desensitization or internalization of MORs. In contrast, morphine does not
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promote detectable internalization of MORs in cultured cells after prolonged or acute
treatment, although it is well established that morphine causes the development of
antinocjceptive tolerance in vivo 56). Thus, the mechanisms underlyjng the
development of tolerance to MOR agonists are still complicated. A potential limitation
of our present understanding is that it is derived, in part, from multiple in vitro studies
using several cell lines including the non-neural cell model. Therefore, in order to
further understand properties of antinociceptive tolerance, I should investigate the utility
of repeated treatment with MOR agonists at doses for the relief of the chronic pain
associated with physiological change in endogenous MOR system and its related
downstream signaling machinery.
   The aim of the present study was then to inyestigate whether repeated administration
of morphine or fentanyl could cause the development of tolerance to the morphine- or
fentanyj-induced antinociceptiye effects under the long-lasting pain-like state induced by
intraplantar administration of CFA in mice. Additionally, I compared the effect of
repeated administration of morphine or fentanyl on the regulatory process of MOR
trafficking, which is responsible for receptor phosphorylation, internalization and
recycling pathways following CFA injection in mice.
15
                           Materials and Methods
Animals
    Male CXBK (The Jackson Laboratory, Bar Harbor, ME, USA and Tokyo
Laboratory Animals Science Co., Tokyo, Japan), male C57BL/6J and ICR mice
(Tokyo Laboratory Animals Science, Tokyo, Japan), weighing 22-30 g at the beginning
of experiments, were housed in groups of 8-10 in a temperature-controlled room
(23Å}10C).
Drugs
    The drugs used in the present study were morphine hydrochloride (Sankyo Co.,
Tokyo, Japan), fentanyl citrate (Hisamitsu Pharmaceutical Co., Tokyo, Japan) and CFA
(Sigma Chemical Co., St. Louis, MO, USA). Morphine and fentanyl were dissolved in
O.99o saline.
Measurement of thermal hyperalgesia
    To assess the sensitivity to thermal stimulation, each of the hind paws of mice was
tested individually using a thermal stimulus apparatus (UGO-BASILE, Biological
Research Apparatus, VA, Italy). The intensity of the thermal stimulus was adjusted to
achieve an average baseline paw withdrawal latency of approximately 8 to 10 sec in
naive mice. Only quick hind paw movements (with or without licking of the hind
paws) away from the stimulus were considered to be a withdrawal response. Paw
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movements associated with locomotion or weight shifting were not counted as a
response. The paws were measured alternating between the left and right 'with an
interval of more than 3 min between measurements. The latency of paw withdrawal
after the thermal stimulus was determined as the ayerage of three measurements per
paw.
    In the experiment of anti-hyperalgesic tolerance to opioids with repeated s.c.
injection of morphine or fentanyl, mice were repeatedly injected with saline, morphine
(3 mg/kg, s.c.) or fentanyl (30 ptglkg, s.c.) once a day for 15 consecutive days after
saline or CFA injection. Measurement of thermal threshold was performed just before
and 30 or 15 min after s.c. injection of saline, morphine or fentanyl on day 1, 7 and 15.
Finally, 9ro of reverse with standard error was calculated as ((Ti - To)/(Tday o - Td.y i)) Å~
100, where To and Ti were thermal threshold before and after the s.c. injection of
morphine or fentanyl on each test day and Td,, o was thermal threshold before CFA-
injection and Td,y i was thermal threshold 1 day after CFA-injection.
Western blotting assay
    The membrane fraction was prepared following the method described previously 5D.
An aliquot of tissue sample was diluted with an equal volume of electrophoresis sample
buffer (Protein Gel Loading Dye-2x; AMRESCO, Solon, OH, USA) containing 29o
sodium dodecyl sulfate (SDS) and 109o glycerol with O.2 M dithiothreitol. Proteins
(10-20 gegllane) were separated by size oR 5-209o SDS-polyacrylamide gradient gel and
transferred to a nitrocellulose membrane in a buffer containing 25 mM Tris and 192 mM
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glycine. For immunoblot detection of protein kinase C y (PKCy), phosphorylated-PKC
(activated form of PKC, p-PKC), G protein-coupled receptor kinase 2 (GRK2),
phosphorylated-protein kinase A (activated form of PKA, p-PKA), phosphorylated-
MOR (p-MOR, Ser 375), phosphorylated-protein phosphatase 2A (p-PP2A, Tyr 307)
and Rab4, membranes were blocked in Tris-buffered saline (TBS) containing O.39o
nonfat dried milk (NAKARAI TESQUE, Inc., Kyoto, Japan) for 1 hr at room
temperature with agitation. The membrane was incubated with primary antibody
diluted in TBS containing O.39o nonfat dried milk [1:1000 p-MOR (Cell Signaling
Technology Inc., MA, USA), 1:2ooO p-PP2A (Santa Cruz Biochemicals, Inc., CA,
USA), 1:5000 Rab4 (Santa Cruz Biochemicals, Inc., CA, USA), 1:4000 PKCy (Santa
Cruz Biochemicals, Inc., CA, USA), 1:1000 p-PKC (Ceil Signaling Technology Inc.,
MA, USA), 1:1500 GRK2 (Santa Cruz Biochemicals, Inc., CA, USA) and 1:1000 p-
PKA (UPSTATE Inc., NY, USA)] overnight at 4 eC. The membranes were washed in
Tween 20-TBS (TTBS) and then incubated for 2 hr at room temperature with
horseradish peroxidase-conjugated goat anti-rabbit IgG (Southern Biotechnology
Associates, Inc., Birmingham, AL, USA), which was diluted 1:10,ooO in TBS
containing 59o nonfat dried milk. After this incubation, the membranes were washed
in TTBS. The antigen-antibody-peroxidase complex was then finally detected by
enhanced chemiluminescence (PIERCE, Rockford, IL, USA) and visualized by
exposure to Amersham Hyperfilm (Amersham Life Sciences, Arlington Heights, IL,
USA). Film autoradiograms were analyzed and quantified by computer-assisted
densitometry using NIH Image.
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Statistical data analysis
    The data are expressed as the mean with standard error of the mean (S.EM.). The
509o effective concentration (ECso) and 509o inhibitory concentration (ICso) was
calculated by GraphPad Prism Programs version 3.0 (GraphPad Software Inc., CA,
USA). The statistical significance of differences between the groups was assessed by
one-way or two•-way analysis of variance (ANOVA), followed by the Bonferroni test or
Student's t-test.
19
Results
Effect of single or repeated s.c. injection of morphine or fentanyl on thermal
hyperalgesia induced byintraplantar injection of CFA in mice
    Unilateral intraplantar injection of CFA into the mouse hind paw caused a marked
decrease in the latency of paw withdrawal against a thermal stimulus only on the
ipsilateral side in ICR mice (Fig. IA and B). The persistent painful state caused by
intraplantar injection of CFA lasted for more than 14 days following CFA treatment in
mice (data not shown). The single s.c. injection of either morphine (1-10 mg/kg) or
fentanyl (10-1oo ptg/kg) 1 day after CFA treatment recovered the decreased thermal
threshold observed on the ipsilateral side in CFA-treated mice in a dose-dependent
manner (Fig. IA and B). At dose of 3.0 mg/kg or 30 pg/kg, s.c. administration of
morphine or fentanyl, respectively, almost completely reversed the decrease in the
thermal threshold without excessive effects in CFA-treated mice. Therefore, we
proposed that the optimal doses for morphine- and fentanyl-induced anti-hyperalgesic
effects in CFA-pretreated mice were 3.0 mg/kg and 30 pg/kg, respectively. As shown
in figure IC, the thermal hyperalgesia observed on the ipsilateral side after CFA
injection was clearly reversed by each repeated s.c. injection of morphine (3 mg/kg)
once a day for 15 consecutive days after CFA injection (Fig. IC). On the contrary, the
anti-hyperalgesic effect following the chronic treatment with fentanyl (30 ptg/kg) was
gradually tolerated (Fig. IC).
Changes in levels of p-MOR, p-PP2A and Rab4 following repeated s.c. injection of
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morphine or fentanyl in the spinal cord of CFA-pretreated mice
    Westem blots showed that the levels of p-MOR in the spinal cord were
significantly increased following intraplantar administration of CFA compared to those
in saline treated-mice (pÅqO.Ol; Fig. 2). Repeated s.c. administration of morphine
induced a significant increase (pÅqO.OOI) in p-MOR levels in the spinal cord obtained
from CFA-pretreated, but not saline-pretreated, mice compared to saline-saline treated
group. On the other hand, the levels of p-MOR in the spinal cord were significantly
increased following repeated s.c. treatment with fentanyl in either saline- or CFA-
pretreated mice compared to those in saline-saline treated-group. As shown in figure 3,
the immunoreactivities of PKCy, p-PKC (activated form of PKC jsoforms) , GRK2 and
p--PKA (activated form of PKA) were not significantly different in the spinal cord of
both saline- and CFA-pretreated mice following consecutive administration of morphine
or fentanyl.
    We next evaluated the effect of repeated s.c. treatment with morphine or fentanyl
on the levels of p-PP2A, which is inactivated form of PP2A, in the spinal cord obtained
from mice pretreated with CFA. As shown in figure 4A, we found that repeated s.c.
treatment with fentanyl produced a significant increase in leyels of p-PP2A in plasma
membranes of the spinal cord obtained from CFA-, but not saline-, pretreated mice
(pÅqO.OOI). In contrast, the level of p-PP2A following repeated injection of morphine
in CFA-treated mice was similar to that in saline-treated mice.
    As shown in figure 4B, s.c. treatment with fentanyl (30 pg/kg) produced a
significant decrease in the expression of Rab4 in the spinal cord obtained from CFA--
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pretreated, but not saline-pretreated, mice (pÅqO.OOI). In contrast, the same treatment
with either saline or morphine failed to affect the expression of Rab4 in the spinal cord
obtained from CFA-treated mice.
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Fig. 1 Effect of s.c. injection of morphine or fentanyl on the latency of paw Nvithdrawal in response to
thermal stimulus on the ipsilateral side in saline- or complete Freund's adjuvant (CFA)-injected mice.
Measurement of thermal threshold was pert'ormed just before and 30 or 15 min after s.c, injection of
morphine or fentanyl, respectively. Groups of mice were treated s.c. with morphine (1-10 mglkg)
(A) or fentanyl (10-100 pglkg) (B) 1 day after CFA injection. Each column represents the mean Å}
S.E.M. of 8-10 mice. """pÅqO.OOI vs. Saline-saline group. ##pÅqO.Ol and ###pÅqO.OOI vs. CFA-
saline group. (C) Mice were repeatedly injected with saline, morphine (3 mglkg) or fentanyl (30
u,gfkg) once a day for 15 consecutive days after sa]ine or CFA injection. Measurement of thermal
threshold was performed l, 7 and 15 days after CFA injection. Each point represents the mean Å}
S.E.M. of 8-10 mice. *pÅqO.05 and ***pÅqOOOI vs. CFA-saline group on each test day. ###pÅqO.OOI
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Fig. 2 Changes in levels of p-MOR (Ser 375) in membranes of the mouse spinal cord after repeated
morphine (3 mglkg) or fentanyl (30 ptglkg) treatment in saline- or CFA-injected mice. Upper:
Representative Western blot for p-MOR. Lower: Change in the immunoreactivity for p-MOR in
membranes of the spinal cord obtained from saline-, morphine- or fentanyl-treated mice with saline-
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ptgfkg) once a day for 15 consecutive days following CFA injection. The membrane fraction was
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Fig. 3 Changes in levels of PKCy (A), p-PKC (B), GRK2 (C) and p-PKA (D) in membranes of the
mouse spinal cord after repeated morphine (3 mglkg) or fentanyl (30 uglkg) treatment in saline- or
CFA-injected mice. Upper: Representative Westem blot of each protein. Lower: Change in the
immunoreactivity for each protein in membranes of the spinal cord obtained from saline-, morphine-
or fentanyl-treated mice with saline- or CFA-injection. Mice were repeatedly injected with saline,
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Discussion
   In the present study, an inflammatory pain-like state induced by intraplantar
injection of CFA was suppressed by s.c. treatment with either morphine or fentanyl in a
dose-dependent manner. At dose of 3.0 mglkg or 30 yglkg, s.c. administration of
morphine or fentanyl, respectively, completely reversed the decrease in the thermal
threshold without excessive effects in CFA-treated mice. The key fiRding in the
present study is that the anti-hyperalgesic effect induced by fentanyl in CFA-pretreated
mice was rapidly disappeared during consecutive administration of fentanyl (30 pglkg).
On the contrary, morphine (3 mglkg) preserved its potency of anti-hyperalgesic effect in
CFA-pretreated mice even following repeated s.c. treatment with morphine. To our
knowledge, these results are the first to indicate that the consecutive injection of
fentanyl, unlike morphine, may extensively induce the development of tolerance to its
anti-hyperalgesic effect under the persistent pain state.
   A growing body of evidence suggests that the phosphorylation of MOR at diverse
sites of its intracellular domain by GRK or second messenger-regulated protein kinases
such as PKC and CaMKII has been shown to trigger the internalization of
phosphorylated MOR from the cell surfa, ce to the cytosol `8). These processes are
thought to be an important step toward receptor desensitization. Among diverse
serinelthreonine residues of intracellular domain of MOR, phosphorylation of Ser 375
in the mouse MOR is essential for its internalization. In the present study, I found that
the intraplantar injection of CFA resulted in an increase in levels of p-MOR (Ser 375) in
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plasma membranes of the spinal cord. Consistent with this result, Narita et al. 39)
previously reported that p-MOR-like-IR was clearly increased on the ipsilateral side in
the superficial laminae of the L5 lumbar spinal dorsal horn under the long-lasting pain-
like state induced by sciatic nerve ligation. A number of previous reports suggest that
either PKCy, GRK2 or PKA can be directly activated in response to the stimulation of
MOR 58'oo). Subsequently, it is considered that activated PKCy and GRK2
phosphorylate Ser 375 in the mouse MOR `8). However, Westem-blot analysis
revealed no significant differences in levels of PKCy, p-PKC, GRK2 and p-PKA in the
spinal cord between saline- and CFA-pretreated mice following consecutive
administration of morphine or fentanyl. It is of interest to note that repeated s.c.
treatment with fentanyl further increased the protein level of p-MOR (Ser 375) in
plasma membranes of the spinal cord under the inflammatory pain-like state. In
contrast, the same treatment with morphine failed to affect the protein level of p-MOR
(Ser 375) in the spinal cord. These results suggest that repeated injection of fentanyl,
but not morphine, may markedly facilitate the phosphorylation of MOR in CFA-
pretreated mice compared to that in saline-pretreated mice. After phosphorylation of
Ser/Thr residues of the C-terminus, MORs are mostly internalized yia clathrin-coated
pits into early endosomes and subsequently dephosphorylated by intracellular protein
phosphatases, such as PP2A 6i). The dephosphorylated MORs might be either recycled
through soning endosomes back to the plasma membrane or transported to the
lysosomes for degradation. Here I also found that the protein level of p-PP2A (Tyr
307), which is the inactivated form of PP2A, in plasma membranes of the spinal cord
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obtained from CFA-injected mice was significantly increased by repeated treatment
with fentanyl, but not morphine. These findings point out the possibility that chronic
pain may cause the different modulation on the process of the opioid receptor turnover
between chronic morphine and fentanyl treatments. This hypothesis can be supported
by the present immunoblotting studies examining the changes in levels of Rab4, which
is the one of Rab GTPase, in the spinal cord of mice with chronic opioid treatment
following CFA injection. Rab GTPase with over 60 members regulate intracellular
vesicular membrane transport and membrane fusion events, Generally, it has been
widely accepted that Rab4 localizes on the endocytic vesicle and participates in
recycling process of receptor protein from early endosomes to the plasma membrane 6S.
In the present study, the protein level of Rab4 in plasma membranes of the spinal cord
obtained from CFA-injected mice was dramatically decreased by repeated treatment
with fentanyl. On the contrary, the protein level of Rab4 following repeated injection
of morphine in CFA-treated mice was similar to that in saline-treated mice. These
results suggest that repeated treatment with fentanyl under the inflammatory pain state
may lead to the facilitation of MOR phosphorylationlinternalization and the attenuation
of sorting internalized MOR back to the plasma membrane, whereas morphine does not
cause such an event. The jnduction of MOR phosphorylationlinternalization and the
inhibiting MOR resensitization following the consecutive injection of fentanyl under the
inflammatory pain state may directly contribute to the development of tolerance to
fentanyl-induced antinociception in mice with CFA injection.
   In conclusion, I demonstrated here that repeated treatment with fentanyl causes a
                                  29
rapid desensitization to its anti-hyperalgesic effect under the inflammatory pain state,
whereas morphine does not produce this phenomenon. Repeated treatment with
fentanyl, but not morphine, results in the increase in levels of p-MOR associated with
the enhanced inactivation of PP2A and the reduction in Rab4-dependent MOR
resensitization. Although further experiments are still needed, this phenomenon
provides the first evidence for the mechanism underlying the development of tolerance
to fentanyl-induced antinociception under chronic pain-like sate.
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Chapter 2
Reduced expression of a novel MOR subtype MOR-IB in CXBK mice:
Implications of MOR-IB in the expression of MOR-mediated
responses
31
Introduction
   The MOR serves as the principle physiological target for the most clinically
important opioid analgesics, including those with high addiction liability. It has been
shown that MOR, as well as other opioid receptors, transduces signals through pertussis
toxin (PTX)-sensitive Gi/Go proteins to inhibit adenylate cyclase, increase membrane
K' conductance and reduce Ca2' current 63).
   The main two MOR subtypes, pti and pt2, have been proposed by a variety of
receptor binding afld pharmacological studies 6`'65). The naloxonazine-sensitive pti-
receptor subtype is thought to play an important role in supraspinal analgesia, whereas
the naloxonazine-insensitive F,t2-receptor subtype mediates spinal analgesia, respiratory
depression and inhibition of gastrointestinal transit 66'6".
   Many GPCR genes contain introns, which introduce the possibility of yariants due
to alternative splicing. Variations in gene-product splicing occur at the level of
processing of heteronuclear-RNAs in the cell nucleus. A growing body of evidence
suggests that alternative splicing with 14 exons results in several spliced variants for the
cloned MOR '9' 20). Several splice variant-dependent MOR subtypes that are different
in length and amino acid composition only at the jntraceljular carboxyl terminus have
been identified. Among the isolated variants, MOR-1 that has exon 1, 2, 3 and 4, and
MOR-IB that contains an alternatively spliced exon 5 instead of the original exon 4,
retain unique biochemical profiles 2"22). Following agonist stimulation, MOR-IB
shows an accelerated cycle of receptor endocytosis and reactivation, which in turn
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promotes a greater resistance to agonist-induced desensitization than MOR-1 2i'as). It
should be mentioned that the MOR gene-targeted studies using mice with either a
deletion of exon 1, 2 or 3 failed to distinguish the pt,- and pt,-receptor subtypes 68'7').
Although two subtypes may result from differential transcriptional modification, no
report on the identification of pti and pt2 subtypes at the molecular leyel has been
provided so far. It is of interest to note that a selective pti-receptor antagonist
naloxonazine binds to MOR-IB as well as MOR-1, indicating the possibility that MOR-
IB can encode pi-receptor subtype 2').
   The CXBK mouse strain, which has been used in many studies to analyze the
function of pti/pt2 subtypes, is a recombinant-inbred strain derived by mating from a cross
between C57BL16J and BALBIc mice. This strain exhibits a significant lower levels of
MOR in the brain area involving pain processing than those in its progenitor strains 72).
Autoradiographic studies have demonstrated that CXBK mice reveal a less density of the
pti-receptor binding sites '2). In the previous study, I demonstrated that the
antinociceptive effect of intracerebroventricular (i.c.v.)-administered morphine or
fentanyl, which was thought to be mediated by pti-receptor, was markedly reduced in
CXBK mice 73). The present study was then to investigate whether CXBK mice could
be deficient in a putative splice variant-dependent MOR subtype.
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Materials and Methods
Animals
   Male CXBK and C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME, USA
and Tokyo Laboratory Animals Science Co., Ltd., Tokyo, Japan), weighing 20-30 g at
the beginning of experiments, were housed in groups of 8-12 in a temperature-
controlled room. The animals were housed at a room temperature of 22 Å} 10C with a 12
hr light-dark cycle (light on 8:OO am to 8:OO pm). Food and water were available ad
libitum.
RNA preparation and semi-quanthative analysis by reverse transcription-
polymerase chain reaction (RT-PCR)
   Total RNA obtained from the mouse whole brain (except cerebellum) was extracted
using the SV Total RNA Isolation system (Promega Co., Madison, WI, USA). First-
strand cDNA was prepared as described 7`) and the MOR gene was amplified in 50 ptL
of a PCR solution containing O.8 mM MgC12, dNTP mix, and DNA polymerase with
either synthesized primers of MOR-1 (sense: 5'-GCA TCC CAA CTT CCT CCA CAA
TCG-3', antisense: 5LCCA GGA AAC CAG AGC erC CCA CAA-3') or MOR-IB
(sense: 5'-CAA AAT ACA GGC AGG GGT CCA-3', antisense: 5'-AAT Aer ATT TTC
TGG TGG TTA GTT C-3'). Samples were heated to 940C for 2 min, 55Åé for 2 min,
and 72Åé for 3 min and cycled 39 times through 940C for 1 min, 55Åé for 2 min, and
72Åé for3 min. The final incubation was at 720C for7 min. The mixture was subjected
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to 19o agarose gel that for electrophoresis with the indicated markers and primers for the
internal standard P2-microglobulin (P,-MG). Each sample was applied more than two
lanes in the same gel. The agarose gel was stained with ethidium bromide and
photographed with UV transillumination. The intensity of the bands was analyzed and
quantified by computer-assisted densitometry using an NIH image. For the control, the
different intensities of each band provided from the sample of C57BU6J mice were
analyzed, and the average intensity was calculated. Then, each control intensity was
again compared with the average intensity to calculate the standard error. Under these
conditions, each intensity of bonds for the sample obtained from CXBK mice was
analyzed and compared with the average intensity of that from C57BL16J mice.
Finally, 9o of control with standard error for the sample of CXBK mice was quantified
with a computer-assisted imaging analysis system (NIH Image).
Immunohistochemistry
   Mice were anesthetized with sodium pentobarbital (70 mg/kg, i.p.) and perfusion-
fixed with 49o paraformaldehyde, pH 7.4. Then, the brains were removed quickly after
perfusion and thick coronal section of the midbrain including periaqueductal gray
matter (PAG) region was initially dissected using Brain Blocker (Neuroscience Inc.,
Tokyo, Japan). The coronal section of the midbrain was post-fixed in 49o
paraformaldehyde for 2 hr. After the brains were permeated with 209o sucrose for 2 days
and 309o sucrose for 2 days, they were frozen in an embedding compound (Sakura
Finetechnical Co., Tokyo, Japan) on isopentane using liquid nitrogen and stored at -30
                                    35
OC until used. Frozen 10 ptm-thick coronal sections were cut with a cryostat (Leica
CM1510; Leica Microsystems, Heidelberg, Germany) and thaw-mounted on poly-L-
lysine-coated glass slides. The brain sections were blocked in 109o normal horse
serum (NHS) in O.Ol M phosphate-buffered saline (PBS) for 1 hr at room temperature.
Sections were incubated in primary antisera to MOR--IB (1:5000) (Gramsch
Laboratories, Schwabhausen, Germany), which recognizes the amino acid sequence
corresponding to the carboxyl-terminal of MORIB (TVDRTNHQKIDLF), 2 overnight
at 4Åé. The antibody was then rinsed and incubated with each secondary antibody for 2
hr at room temperature. For the labeling, AIexa 488-conjugated goat anti-rabbit IgG for
MOR-IB was diluted 1:400 in PBS containing 109o normal horse serum. In the present
study, each slice obtained from CXBK or C57BL16J mice were incubated on the same
slides. The slides were then coverslipped with PermaFluor Aqueous mounting medium
(Immunon; Thermo Shandon, Pittsburgh, PA). Fluorescence immunolabeling was
detected using a U-MNIBA filter cube (Olympus, Tokyo, Japan) for Alexa 488.
Digitized images of PAG sections were captured at a resolution of 1,316 x 1,035 pixels
with camera. The density of MOR-IB labeling was measured with a computer-assisted
imaging analysis system (NIH Image), according to the method described previously 78).
The upper and lower threshold density range were adjusted to encompass and match the
immunoreactivity to provide an image with immunoreactive material appearing in black
pixels, and non-immunoreactive material as white pixels. A standardized rectangle was
positioned over the PAG area of C57BL/6J mice. The area and density of pixels within
the threshold value representing immunoreactivity were calculated and the integrated
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density was the product of the area and density. The same box was then `dragged' to the
corresponding position on the PAG area of CXBK mice and the integrated density of
pixels within the same threshold was again calculated. The value for CXBK mice was
expressed as percentage of control.
[35S]GTPyS binding assay
   For the membrane preparation, whole brain (except cerebellum) was removed from
mice, and rapidly transferred to a tube filled with an ice-cold buffer. The membrane
homogenate (3-8 ptg protein/assay) was prepared as described 76) and incubated at 250C
for 2 hr in 1 mL of assay buffer with various concentrations of endomorphin-1 (O.Ol-10
ptM), 30 ptM guanosine-5'--diphosphate (GDP) and 50 pM t35SIGTPyS (specific activity,
10oo Cilmmol; Japan Radioisotope Association, Tokyo, Japan). The reaction was
terminated by the filtration using Whatman GFIB glass filters. The filters were washed
three times and then transferred to scintillation-counting vials containing tissue
solubilizer (Soluene-350; Packard Instrument Co., Meriden, CT, USA) and scintillation
cocktail (Hionic Fiuor; Packard Instrument Co., Meriden, or, USA). The radioactivity
in the samples was determined with a liquid scintillation analyzer. Non-specific
binding was measured in the presence of 10 ptM unlabeled GTPyS.
Assessment of antinociception
   Antinociception was determined by the tail-flick test. The intensity of the heat
stimulus was adjusted so that the animal flicked its tail after 3-5 sec. The inhibition of
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this tail-flick response was expressed as a percentage of the maximum possible effect,
which was calculated as ((Ti - To)/(T2 - To)) x 100, where To and T, were the tail-flick
latencies before and after the i.c.v. injection of endomorphin-1 (10, 17, 24 nmol/mouse)
and T2 was the cut-ofif time (set at 10 sec) in the tests to avoid injury to the tail. The
antinociceptive effect of endomorphin-1 was measured at 10 min after i.c.v. injection.
Injection procedure
   The i.c.v. administration was performed following the method described previously
7n. In order to make a hole in the skull for the injection, one day before the
administration of antisense oligodeoxynucleotide, mismatch oligodeoxynucleotide or
saline, mice were briefly anesthetized with ether and a 2-mm double-needle (tip: 27GÅ~
2 mm and base: 22GÅ~10 mm, Natsume Seisakusyo Co., Tokyo, Japan) attached to a
25-ptL Hamilton microsyringe was inserted into the unilateral injection site. The
unilateral injection site was approximately 2 mm from either side of the midline
between the anterior roots of the ears. The head of the mouse was held against a V-
shaped holder and the drugs were injected into the hole. The injection volume was 4 ptL
for each mouse. Each solution was injected without injection cannulae.
Administration of antisense oligodeoxynucleotide (AS-ODN) and endomorphin-1
   Synthetic end-capped phosphorothioate AS-ODN and mismatch
oligodeoxynucleotide (MM-ODN), corresponding to exon 5 in MOR-IB cDNA, were
prepared. Sequences were as follows: AS-ODN, 5'-AAA TAA TAC TAT Trl'T-3' and
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MM-ODN , 5'-TAA AAA TCA TTT TAT-3'. C57BL/6J mice were received with saline
(4 ptL/mouse/day), AS-ODN (5 ptg/mouse/day) or MM-ODN (5 yg/mouse/day) injected
i.c.v. into the unilateral ventricle. Single i.c.v. injection of each oligodeoxynecleotide or
saline was performed once daily for 3 days based on the schedule described previously:
i.e. daysl, 2 and 3. An interval of 24 hr was selected between oligodeoxynecleotide
administrations to minimize the neurotoxic damage. On day 4, a selective endogenous
MOR agonist endomorphin-1 (10, 17 and 24 nmol/mouse) was injected into the same
hole of lateral cerebral ventricle with a 25-ptL Hamilton microsyringe and the
antinociceptive effect induced by endomorphin-1 was evaluated by the tail-flick test at
10 min after i.c.v. injection.
Statistical data analysis
   The data are expressed as the mean with S.E.M. The statistical significance of
differences between the groups was assessed by one-way or two-way ANOVA, followed
by the BonferronilDunn multiple comparison test.
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Results
Reduction in the expression of MOR-IB mRNA in the supraspinal site of CXBK
mice as compared to that in their progenitor C57BL/6J mice
   To inyestigate the expressjon of spljced-variant dependent MOR subtypes MOR-1
and MOR-IB mRNAs in the whole brain of CXBK mice, I carried out semi-quantitative
analysis of MOR-1 and MOR-IB mRNAs using RT-PCR assay. The expression of
either MOR-1 or MOR-IB mRNA can be observed in the whole brain obtained from
C57BU6J mice. A single band migrating at 245 and 547 bp was detected for MOR-1
and MOR-IB mRNAs, respectively. In the present study, the level of MOR-IB
mRNA was markedly lower in CXBK mice than that in C57BL/6J mice (pÅqO.05, Fig. 1).
In contrast, there was no significant difference in MOR-1 production between the two
strains (Fig. 1).
Reduction in the level of MOR-IB-like immunoreactivity in the PAG region of
CXBK mice as compared to that in their progenitor C57BL/6J mice
   In the immunohistochemical study, MORIB-IR was distributed in the PAG area in
C57BL/6J mice (Fig. 2A). However, relatively less MOR-IB-IR was seen in the same
subset of the PAG area of CXBK mice (Fig. 2B). A significant decrease in MOR-IB-
IR was detected in the PAG region of CXBK as compared to that in C57BL16J mice
(PÅqO.OOI, Fig. 2C).
ua
Comparison of supraspinal antinociceptive effect and G.protein activation induced
by endomorphin-1 between CXBK and C57BL16J mice
   I next investigated whether CXBK mice could affect the G-protein activation by
MOR agonists in membranes of the whole brain (Fig. 3A). The ability of a selective
endogenous MOR ligand endomorphin-1 to activate G-proteins in the brain of
C57BL16J and CXBK mice was examined by monitoring the binding of l35S]GTPyS to
brain membranes. Endomorphin-1 (O.Ol-10 ptM) produced a concentration-dependent
increase in the binding of [35S]GTPyS to whole brain membranes obtained from
C57BL16J mice. In contrast, the binding of [35S]GTPyS stimulated by endomorphin-1
was signjfjcantly decreased in CXBK mice (PÅqO.Ol or PÅqO.OOI vs. C57BIV6J mice, Fig.
3A).
  Additional evidence for the reduced MOR function in CXBK mice with respect to
the antinociceptive response to endomorphin-1 was obtained in the tail-flick test. The
i.c.v. administration of endomorphin-1 produced a profound antinociception in
C57BL/6J mice. The CXBK mice were virtually devoid of the robust endomorphin-l-
induced antinociception (PÅqO.Ol or PÅqO.OOI vs. C57BL16J mice, Fig. 3B).
Effects of i.c.v. injection of AS-ODN targeting exon 5 of MOR gene on the
expression of MOR-IB and endomorphin-1-induced antinociception in the
supraspinal site
   Finally, I examined whether the knockdown of MOR-IB expression by i.c.v.
pretreatment with AS-ODN to exon 5 of MOR in the brain from C57BL16J mice could
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influence the antinociceptive effect of endomorphin-1. The level of MOR-IB mRNA
was detectable in the whole brain obtained from C57BL16J mice treated i.c.v. with
either saline or the MM-ODN to exon 5 of MOR with the same degree, whereas i.c.v.
treatment with AS-ODN to exon 5 of MOR produced a significant decrease in MOR-1B
mRNA Ievels (pÅqO.05 vs. saline, Fig. 4A, B). In contrast, the same treatment produced
no significant difference in leyels of MOR-1 expression (Fig. 4A, B). Under these
conditions, the dose-response lines for the endomorphin-1-induced antinociception in
C57BL16J mice pretreated with either saline or the MM-ODN to exon 5 of MOR were
markedly shift to the right by pretreatment with AS-ODN to exon 5 of MOR (PÅqO.Ol or
PÅqO.OOI vs. saline or MM-ODN, Fig. 4C), being in good agreement with the findings in
CXBK mice (shown in Fig. 3B).
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Fig. 1 Reduced expression of MOR-IB mRNA in the whole brain of CXBK mice. (A) Representative
RT-PCR for MOR-1 and MOR-IB mRNAs in the brain obtained from C57BL16J (C57BL) and
CXBK mice. The sample mixture was subjected to 1 9o agarose gel electrophoresis with the indicated
markers and primerg. for the internal standard B2-MG. Six experiments using three independent
samples were performed in this study. (B) Semi-quantitation of the intensity of the bands. The value
for CXBK mice is expressed as a percentage against C57BL mice. Each coiumn represents the mean
Å} S.E.M. of six experimentg. . "pÅqO.05 vs. C57BL mice.
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Fig. 2 Reduccd MORIB-Iike immunoreactivity (MORIB-IR) in the PAG of CXBK mice. Coronal
sections including the PAG were obtained from C57BL!6J (C57BL) (A) and CXBK mice (B), Thc
decreased MORIB-IR was detected in the PAG of CXBK mice, Scale bars = 50 ym, (C) Scmi-
quantitative analysis of MOR-IB-IR in the PAG arca of C57BL and CXBK mice. The value for
CXBK mice is expressed as a perccntage of the density as,ainst C57BL micc, Each column represents
thc mean Å} S,E,M, of six experiments,
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Fig. 3 Effect of an endogenous MOR ligand endomorphin-1 on the binding of [35S]GTPyS to
membranes of the whole brain obtained from C57BL16J (C57BL) and CXBK mice. Membranes were
incubated with 50 pM [35S]GTPyS and 30 ptM GDP with or without different concentrations (O.Ol--10
ptM) of endomorphin-1 for 2 hr at 25Åé. The data are expressed as a percentage of basal [35S]GTPyS
binding measured in the presence of GDP and absence of agonist. The data represent the mean Å}
S.E.M., at Ieast, of three independent experiments. "*pÅqO.Ol, *"*pÅqO.OOI vs. C57BL mice. The F
value of two-way ANOVA in endomorphin-1 is F(1, 56)=60.77. (B) Dose-response lines for the
antinociceptive effect produced by i.c.v. administration of endomorphin-1 in C57BL16 and CXBK
mice using a tail-flick assay. Tail-flick latencies were measured at 10 min after i.c.v. injection of
endomorphin-1 (10-24 nmollmouse). Antinociception was expressed as a percentage of the maximal
possible effect (9o Antinociception). The data represent the mean Å} S.E.M. of 6-8 mice. "'pÅqO.Ol,
***pÅqO.OOI vs. C57BLmice.
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Fig. 4 (A) Representative RT-PCR for MOR-1 and MOR-IB mRNAs in the brain obtained from
C57BL16 mice following treatment with saline or antisense oligodeoxynucleotide against exon 5 of
MOR (AS-Ex5). An i.c.v. pretreatment with saline, AS-Ex5 (5 ptglmouse) and mismatch
oligodeoxynucleotide (MM-Ex5, 5 uglmouse) against exon 5 of MOR were perfoirmed once a day for
3 days. On day 4, the samples for RT-PCR were obtained from each group. The sample mixture was
subjected to 1% agarose gel electrophoresis with the indicated markers and primers for the internal
standard 62-MG. Six experiments using three independent samples were perfoimed in this study. (B)
Semi-quantitation of the intensity of the bands. The value for mice pretreated with AS-Ex5 is
expressed as a percentage of the increase in mice pretreatment with saline. Each column represents
the mean Å} S.E.M. of six experiments. 'pÅqO.05 vs. saline group. (C) Effect of AS-Ex5 on the
endomorphin-1-induced antinociception in C57BL16J mice. The data represent the mean Å} S.E.M. of
6-8 mice. *'pÅqO.Ol, ***pÅqO.OOI vs. saline groups. ##pÅqOOI vs. MM-Ex5 group,
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Discussion
   In the present study, I demonstrated for the first time that CXBK mice display a
significant reduction in the expression of MOR-IB mRNA in the brain as compared to
that in their progenitor C57BL16J mice. In contrast, the expression level of MOR-1
mRNA in the brain of CXBK mice was similar to that found in C57BL16J mice,
indicating a specific loss of MOR-IB mRNA expression in this strain.
   To further clarify whether CXBK mice could exhibit lower levels of MOR-IB
protein in the brain, the immunohistochemical study was performed using the specific
antibody to MOR-IB. In the PAG of CXBK mice, relatively lower levels of MOR-IB-
IR were detected as compared to those observed in C57BL/6J mice. The present data
indicate that the reduction in mRNA expression of MOR-IB in CXBK mice leads to a
decrease in levels of MOR-IB protein in the PAG compared to those in C57BL16J mice.
Such findings stroRgly support my hypothesis that CXBK strain can be classified as
MOR- IB-knockdown mice.
   Since CXBK mice had a lower level of MOR-IB expression in the PAG than that
observed in C57BL/6J, I next examined whether a significant deficiency of MOR-IB in
CXBK mice could affect the MOR function to activate G-proteins. As I expected, the
increase in [3SS]GTPyS binding to whole brain membranes induced by a selective MOR
agonist endomorphin-1 in C57BL16J mice was significantly decreased in CXBK mice.
These results suggest that a less ability to stimulate G-protein via MOR in CXBK mice
may result from the decreased Ievel of MOR-IB expression.
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   It has been reported that alternative splicing with ten to twelve exons results in
seven or more spliced variant for the cloned MOR (ex. MORI and MORIA-MORIF).
Previous immunohistochemical study demonstrated that MOR-1-IR is found abundantly
in the striatum, whereas no MOR-IC--IR is detected in the same region 25). Furthermore,
MOR-IC, but not MOR-1, are distributed in the superficial laminae of the dorsal horn,
and involved in presynaptic inhibition of transmitter release from peptide-containing
afiferents to the dorsal horn 26). Considering these findings, it can be speculated that
each splice variants derived from the same MOR gene reveals a differential distribution
in the CNS and regulates individual physiological and pharmacological function. In
term of MORIB, although there are increasing evidences that MOR-IB regulates some
biochemical functions including receptor trafficking 22), the inhibition of forskolin-
induced cAMP accumulation 2i) and the increase in intracellular Ca2" concentration
resulting from the stimulation of inositol trisphosphate formation '8), the role of MOR-
IB in behavioral effects of MOR agonists was not fully understood. In the present
study, I found that i.c.v. treatment with AS-ODN to exon 5 of MOR produced a specific
reduction in the expression of MOR-IB mRNA, and a significant suppression of the
i.c.v.-administered endomorphin-1-induced antinociception. Furthermore, MOR--IB-
knockdown CXBK mice showed reduced antinociceptive effect of endomorphin-i as
compared to that in C57BL/6J mice. These findings strongly suggest that MOR-IB may
be the primary site for the expression of supraspinal antinociception induced by MOR
agonlsts.
   High density of pti-receptor binding site has been obseryed in the PAG, medial
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thalamus and medial raphe, which are considered to be critical sites to regulate the
antinociception of MOR agonists, in rodents '8'so). Especially, the PAG is the major site
involved in the modulation of nociceptive input, through desending inhibitory
serotonergic neurons that project to the spinal cord. Generally, it is considered that the
facilitation of desending systems is modulated by inhibition of y-aminobutyric acid
(GABA)-containing interneuron. Activation of central MOR may lead to the inhibition
of GABA release, resulting in the stimulation of the desending pathway. In the present
study, I found that MOR-IB-IR was prominently expressed and detected in the PAG of
C57BL/6J mice. The finding is inconsistent with the previous report by Schulz et al that
MOR-IB appears to be predominantly localized to the olfactory bulb in the rat.
Conversely, it was reported that the expression of MOR-IB mRNA can be observed in
many brain areas. The highest concentrations of MOR-IB mRNA are detected in the
frontal cortex and the striatum, and the lowest concentrations are found in the olfactory
bulb and the cerebellum 2'). In this point, I found here that, like MOR-1 mRNA,
MOR-IB mRNA is detectable in the whole brain tissue obtained from C57BL16J mice.
Although the specific reason for these discrepancies between previous
immnohistochemical studies and our studies remains unclear, one possibility is that the
discrepancy may result from species differences or different experimental conditions.
Receptor autoradiographic study has demonstrated that the CXBK strain is deficient in
pti-receptor binding site in several brain regions associated with pain regulation 72). It
should be pointed out that i.c.v. pretreatment with an AS-ODN probe targeting the
coding region of exon 5 of MOR gene suppressed supraspinal antinociception by
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endomorphin-1, which is known to be reversed by a pi-receptor antagonist
naloxonazine '9). Although further experiments are needed to perform, it is likely that
the pti-receptor is closely related to the MOR-IB.
   In conclusion, the present study provides new insights into the mechanism
underlying the reduced antinociceptive response to MOR agonists in CXBK mice.
Furthermore, I propose here that a MOR gene-derived alternative splice variant, MOR--
IB may be a candidate to express a less activity of MOR agonists in the CXBK
phenotype, and play an important role in supraspinal antinociception of MOR agonists.
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Chapter 3
The specific involvement of the opioid receptor types and
subtypes in antinociceptive properties of morphine and fentanyl
MOR
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Introduction
   According to the WHO guidelines for patients with moderate or severe pain, a
typical MOR agonist morphine has been a "gold standard" for treatment of moderate to
severe cancer pain. The intrathecal administration of morphine has been the standard
therapy to control long-term intractable pain. However, the use of morphine is
sometimes accompanied by side effects such as emesis and constipation co'`i). In 1959,
fentanyl, the anilidopiperidine class of MOR agonist, was reported as a potent synthetic
analgesic with a lower propensity to produce these undesirable effects in the clinical
setting. The low molecular weight and lipid solubility of fentanyl make it possible for
delivery via the transdermal therapeutic system. To date, a number of studies
concerning differences of the antinociceptive property between morphine and fentanyl
have been undertaken. It has been well established that fentanyl has a high affinity for
MORs and exhibits 50-100 times more potent analgesic activity than that of morphine
42). In addition, as mentioned in Chapter 1, I demonstrated that the anti-hyperalgesic
effect induced by fentanyl in CFA-pretreated mice was rapidly disappeared during
consecutive administration of fentanyl, whereas morphine preserved its potency of anti-
hyperalgesic effect in CFA-pretreated mice even following repeated s.c. treatment with
morphine. However, the certain mechanisms underlying antinociception induced by
each MOR agonist are not fully understood. It is likely that the reason for the limited
application of morphine or fentanyl in the clinical setting is related to a poor
understanding the difference of certain mechanisms underlying the antinociceptive
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effects of these MOR agonists.
   Several genetic mouse models of differential sensitivity to opioids have been used to
investigate the mechanisms underlying individual variation in responses to opioids.
Among a number of mouse models, the CXBK mouse strain has been used in many
studies to analyze the functional role of MOR subtypes in the CNS. It has been widely
accepted that CXBK mice are recombinant inbred mice derived by full-sib mating from
a cross between the C57BL/6J and BALB/cJ strains. CXBK mice have a partial
deficiency of MOR 52), and the level of MOR mRNA in the brain of CXBK mice is
reduced to approximately 609o of their progenitor mice 55). As shown in Chapter 2, I
found that CXBK strain can be classified as supraspinal MOR-IB-knockdown mice,
and MOR-IB plays an important role in supraspinal antinociception of the endogenous
MOR agonist endomorphin-1. It is therefore worthwhile to use CXBK mice to further
investigate the mechanisms underlying the antinociceptive effects induced by MOR
agonists such as morphine and fentanyl.
   Thus, the goal of the present study was to clarify the analgesic properties of
morphine and fentanyl in the mouse supraspinal and spinal cord. I investigated the
effects of pretreatmefit with MOR, DOR and KOR antagonists, P-FNA, NTI and nor-
BNI, respectively, on the antinociceptive effect induced by morphine or fentanyl using
the mouse tail-flick test. In addition, I compared EDso values for antinociceptive
effects between morphine and fentanyl at peripherai, spinal and supraspinal site,
respectively in ICR mice. Finally, I tired to investigate the specific involvement of
MOR subtypes at either the spinal or supraspinal site in antinociceptive properties of
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morphine and fentanyl using CXBK mice.
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Materials and Methods
Animals
   Male ddY (20-30 g), male ICR (20-30 g), male CXBK (20-30 g) and C57BL/6J (20-
30 g) mice were obtained from Tokyo Laboratory Animals Science Co. (Tokyo, Japan).
The animals were housed at a room temperature of 22 Å} 1 OC with a 12 hr light-dark
cycle (light on 8:30 a.m. to 8:30 p.m.), and were aliowed to adapt to this environment
for 3 days before the experiments. Food and water were available ad libitum.
Drugs
   The drugs used in the present study were fentanyl citrate (Hisamitsu Pharmaceutical
Co., Tokyo, Japan), morphine hydrochioride (Sankyo Co., Tokyo, Japan), P-INA, NTI,
cyclic-[D-Pen2, D-Pen5] enkephalin (DPDPE), nor-BNI and trans-3,4-dichloro-N-(2--(1-
pyrrolidinyl)-cyclohexyl)benzene-acetamide (U-50,488H) (Toray Industries, Kanagawa,
Japan) and CFA (Sigma Chemical Co., St. Louis, MO, USA). P-FNA (40 mg/kg),
naloxonazine (35 mg/kg), NTI (3 mg/kg) and nor-BNI (3 mglkg) were administered s.c.
24 hr, 24 hr, 30 min and 4 hr, respectively, before morphine or fentanyl injection. All
opioid agonists and antagonists were dissolved in saline.
RNA preparation and semi-quantitative analysis by RT-PCR
    Total RNA obtained from the spinal cord of CXBK or
extracted using the SV Total RNA Isolation system (Promega Co.,
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C57BU6J mice was
Madison, WI, USA).
First-strand cDNA was prepared as described previously by Narita et al. '`) and the
MOR gene was amplified in 50 pL of a PCR solution containing O.8 mM MgCl2, dNTP
mix, and DNA polymerase with either synthesized primers of MOR (sense: 5'--AGA
cr6 CCA ACC AAC ATC TAC AT-3', antisense: 5'-TGG ACC CCT GCC TGA TAT
T"I'r G-3'), MOR-1 (sense: 5'--GCA TCC CAA CTT CCT CCA CAA TCG-3', antisense:
5'-CCA GGA AAC CAG AGC CrC CCA CAA-3') or MOR-IB (sense: 5'-CAA AAT
ACA GGC AGG GGT CCA-3', antisense: 5'-AAT ACT ATT TTC TGG TGG TTA
GTT C-3'). Samples were heated to 940C for 3 min, 55Åé for 1 min, and 720C for 1
min and cycled 29 times through 94Åé for 30 sec, 55Åé for 1 min, and 720C for 1 min.
The final incubation was at 72Åé for 7 min. The mixture was subjected to 29o agarose
gel that for electrophoresis with the indicated markers and primers for the internal
standard (GAPDH). Each sample was applied more than two lanes in the same gel. The
agarose gel was stained with ethidium bromide and photographed with UV
transillumination. The intensity of the bands was analyzed and quantified by
computer-assisted densitometry using an NIH image. For the control, the different
intensities of each band provided from the sample of C57BL16J mice were analyzed,
and the average intensity was calculated. Then, each control intensity was again
compared with the average intensity to calculate the standard error. Under these
conditions, each intensity of bonds for the sample obtained from CXBK mice was
analyzed and compared with the average intensity of that from C57BL16J mice.
Finally, 9(o of control was quantified as described in Chapter 2.
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Assessment of antinociception
   Antinociception was determined according to the method described in Chapter 2.
I.t. injection
    I.t. administration was performed according to the method described previously 80)
using a 25 pL Hamilton syringe with a 30 gauge needle. The injection volume was 4 ptL
for each mouse. Each solution was injected without injection cannulae.
Competitive displacement binding
    For the membrane preparation, the spinal cords of mice were quickly removed 24
hr after repeated morphine (10 mg/kg, s.c.) injection and rapidly transferred to a tube
filled with ice-cold buffer. The membrane homogenate was prepared as described
previously 7`). Briefly, the dissected tissue was homogenized in ice-cold buffer
containing 50 mM Tris-HCI (pH 7.4), 5 mM MgCl, and 1 mM ethylene glycol-bis (2-
aminoethylether)-N,N,AI',N'-tetraacetic acid (EGTA). The homogenate was
centrifuged at i,ooO x g for 10 min at 4 eC and the supernatant was ultracentrifuged at
48,OOO x g for 20 min at 4 OC. The pellet was suspended in ice-cold assay buffer
containing 50 mM HEPES (pH 7.4) and 2 mM MgC12 followed by centrifugation at
48,OOO x g for 20 min at 4 OC. The resultant pellet was resuspended in ice-cold assay
buffer and stored at -80 "C until used.
    Binding affinities of morphine or fentanyl to MORs in the spinal cord of ICR mice
were determined by competitive displacement binding with graded concentrations
                                  57
(O.Ol-1oo pM) of unlabeled morphine or fentanyl incubated with 1 nM [D-Ala2,N-Me-
Phe`,Gly5-ol]enkephalin (DAMGO) for 60 min at 250C. Nonspecific binding was
determined using 1 ptM DAMGO. For all competitive binding assays, IC. was
determined from the displacement curves using a one-site model and nonlinear
regresslon.
[35S]GTPyS binding assay
   [35S]GTPyS binding assay was determined according to the method described in
Chapter 2.
Statistical analysis
   The data are presented as the mean Å} S.E.M. The statistical significance of
differences between the groups was assessed with Student's t-test or one-way ANOVA
followed by Bonferroni/Dunnett test.
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Results
Characterization of the antinociception induced by morphine or fentanyl
   Morphine or fentanyl given s.c. produced antinociception, reaching maximal
antinociceptive responses at 15 and 30 min, respectively, after the injection (data not
shown). The antinociception induced by s.c. morphine (3 mglkg) or fentanyl (30
ptg/kg) was significantly attenuated by pretreatment with P-FNA (Fig. IA). In contrast,
NTI (selective 6-receptor antagonist) and nor-BNI (selective K-receptor antagonist) had
no effect on either morphine- or fentanyl-induced antinociception (Fig. IA). The dose
of NTI or nor-BNI used in the present study sufficiently antagonized antinociception
produced by i.c.v.-administered DPDPE (selective 6-receptor agonist) or s.c.-
administered U-50,488H (selective K-receptor agonist), respectively (Fig. IA). When
opioid antagonists were administered at the doses used in the present study, these
antagonists did not produce any changes in the basal tail-flick latency (data not shown).
   The supraspinal antinociception induced by either i.c.v.-administered morphine or
fentanyl was markedly suppressed by pretreatment with P-FNA (Fig. IB). Furthermore,
the i.t-administered morphine- or i.t.--administered fentafiyl-induced antinociception
was significantly attenuated by P-FNA (Fig. IC). Maximal antinocjceptive effect of
morphine or fentanyl was observed at 10-15 min or 5 min, respectively, following each
injection (data not shown).
Comparison of EDso values for antinociceptive effects induced by morphine or
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fentanyl when given s.c., i.c.v. or i.t.
   As shown in figure 2, s.c., i.c.v. or i.t. administration of either morphine or fentanyl
produced significant antinociceptive effects in a dose-dependent manner. In the
present study, I determined the EDse values for s.c.-, i.c.v.- and i.t.-administered
fentanyl- or morphine-induced antinociception (Table 1). In morphine-treated groups,
the EDso values for s.c., i.c.v. and i.t. administrations were 2.58 pmollkg, 1.85
nmol/mouse and O.13 nmol/mouse, respectively. In fentanyl-treated groups, the EDso
values for s.c., i.c.v. and i.t. administrations were O.035 ptmollkg, O.10 nmol/mouse and
O.11 nmol/mouse, respectively. The EDso values for fentanyl-induced antinociceptive
effects following s.c., i.c.v. and i.t. injections were shown in Table 1. The morphine
(MRP)/fentanyl (FEN) ratio for s.c., i.c.v. or i.t route was 73.7, 18.5 or 1.2,
respectively.
Comparison of antinociceptive effects observed in CXBK and C57BL/6J mice at
the supraspinal sites
   The supraspinal antinociceptive effects of morphine (i.c.v.) or fentanyl (i.c.v.) in
CXBK and their parental strain C57BU6J mice were investigated using the tail-flick
test (Fig. 3). In C57BL/6J mice, either morphine or fentanyl produced a dose-
dependent antinociceptive effect. In contrast, CXBK mice significantly exhibited a
weak antinociception induced by i.c.v. administration of both morphine and fentanyl as
compared to that in C57BL/6J mice at the doses used in the present study. (**pÅqO.Ol
and **'pÅqO.OO1)
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Binding affmity of morphine or fentanyl to spinal MORs in ICR mice
    To evaluate the specific involvement of the opioid receptor types and MOR
subtypes in antinociceptive propenies of morphine and fentanyl, I determined the
competitiye displacement binding of l3HIDAMGO with graded concentrations (O,Ol-
100 pM) of unlabeled morphine or fentanyl. As shown in Fig. 4, [3H]DAMGO binding
to the membrane fraction obtained from the spinal cord of ICR mice was completely
displaced by increasing concentrations of either morphine or fentanyl. The
displacement curves for morphine or fentanyl was found to be nearly superimposed.
The ICso values for morphine and fentanyl were 2.02 and 2.47 nM, respectively. On
the other hands, i3H]DPDPE or l3H]U69,593 binding to the membrane obtained from
the mouse spinal cord or the cerebellum of guinea pig, respectively, was not affected by
incubation with morphine or fentanyl (data not shown).
Reduction in the expression of MOR-IB mRNA in the spinal cord of CXBK mice
as compared to that in their progenitor C57BL/6J mice
    To inyestigate the expression of spliced variaBt-dependent MOR subtypes MOR-1,
MOR-IB and overall MORs mRNAs in the spinal cord of CXBK mice, I carried out
semi-quantitative analysis of each mRNA using RT-PCR assay. In the present study,
CXBK mice display a significant reduction in the expression of either MOR or MOR-
IB mRNA in the spinal cord as compared to that in their progenitor C57BL16J mice
(Fig. 5A and B), In the preliminary study, I confirmed that the expression of MOR-IB
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mRNA was completely abolished
observation). In contrast, there was
between the two strains (Fig. 5C).
m
no
MOR gene knockout
significant difference in
mice (unpublished
MOR-1 production
Comparison of the spinal antinociceptive effect and G-protein activation induced
by morphine or fentanyl between CXBK and C57BL/6J mice
    I examined the spinal antinociceptive effects induced by morphine or fentanyl in
CXBK mice (Fig. 6A and B). Either morphine (O.1--1.0 nmol/mouse) or fentanyl
(O.17-3.0 nmollmouse) when given i.t. induced a dose-dependent antinociceptive effect
in C57BL/6J mice (EDso: O.27 or O.41 nmol/mouse, respectively). In contrast, CXBK
mice exhibited significantly a weak antinociception induced by i.t. administration of
morphine or fentanyl as compared to that in C57BL16J mice (EDso: 3.31 or 5.04
nmol/mouse, respectively) (morphine: F(1, 364)=17.84, ***pÅqO.OOI, fentanyl: F(1,
90)=120.20, ***pÅqO.OOI). The dose-response line for antinociceptive effects of
morphine or fentanyl in C57BL16J mice was significantly shifted to right by 12.4- or
12.2-fold in CXBK mice, respectively. I next compared the activation of G-protein
induced by morphine or fentanyl between CXBK and C57BL/6J mice (Fig. 6C and D).
Either morphine or fentanyl (O.oo1-10 ptM) produced a concentration-dependent
increase in the binding of [35SIGTPyS to spinal cord membranes obtained from
C57BL/6J mice. In CXBK mice, the binding of t35SIGTPyS stimulated by either
morphine or fentanyl was significantly decreased compared to that in C57BL16J mice.
The ECse values for morphine in CXBK and C57BL/6J mice were 77.45 and 5.55 ptM,
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respectively. On the contrary, the EC,, values for fentanyl in CXBK and C57BL16J
mice were 32.50 and 3.31 pM, respectively. The ECso values for G-protein activation
induced by either morphine or fentanyl in C57BL16J mice were significantly enhanced
by 13.9- or 9.8-fold in CXBK mice, respectively.
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Fig. 1 (A) LeLfr panel: Effects of 6-FNA, NTI or nor-BNI on s.c. morphine (MRP)- or fentanyl (FEN)-
induced antinociception in the mouse tail-flick test. Right panel: Effects of NTI or nor-BNI on i.c.v.
[D-Pen2, Pen5]enkephalin (DPDPE)- or s.c, U-50,488H-induced antinociception in the tail-flick test.
6-FNA (40 mglkg), NTI (3 mglkg) or nor-BNI (3 mg/kg) was administered s.c. 24 hr, 30 min or 4 hr
before s.c. administration of agonists. *pÅq O.05 and ***pÅq O.OOI vs. saline-pretreated groups. (B)
Effects of fi-INA on i.c.v. MRP- or FEN-induced antinociception in the mouse tail-flick test. 6-ENA
(40 mglkg) was administered s.c. 24 hr before s.c. administration of agonists. ***pÅq O.OOI, ###pÅq
O.oo1 vs. respective agonist alone. (C) Effects of P-FNA on i.t. MRP- or FEN-induced
antinociception in the mouse tail-flick test. B-FNA (40 mg!kg) was administered s.c. 24 h before s.c.
administration of agonists. *"*pÅq O.Ol, ###pÅq O.OOI vs. respective agonist alone. Each bar
represents the mean Å} S.E.M. of 10-15 mice.
64
(A)
g
'a
•es
g
•Åqv=
es"k
Subcutaneous injection
1oo
sc
se
70
oo
so
mp
30
20
 10
 o
 O.oo1 O.Ol O.1 1 10
- Morphine
e Fenunyl
Dose of agonists (mg/kg)
(B)
g
'a
.s
2
kr
*
1oo
Intracerebroventricularinjection
oo
so
70
oo
se
co
30
20
10
o
 O.Ol
- }v(orphine
e Fentanyl
O.1 1
Dose of agonists (nmo!Imouse)
10
(C) Intrathecal injection
  1oo
   go -Morphine
       e Fe•ntanyl
   se
O" 70
'g
8 oo
'2 so
-es
fi 40
* 30
   20
   10
    o
    O.Ol O.1 1
            Dose of agonists (nmol/mouse)
10
Fig. 2 The antinociceptive effect induced by s.c. (A), i.c.v. (B) and i.t. (C) injection of morphine or
fentanyl in ICR mice. The mouse tail-flick assay was performed at 10 or 5 min after i.t. injection of
morphine or fentanyl. Each point represents the mean Å} S.E.M. of 12 mice for each group.
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Table 1 Antinociceptive effects offentanyl (FEN) and morphine (MRP)
EDso values were determined by Litchfrield-Wilcoxon analysis To calculate EDso, at least 3 drug
doses vvere used and 8-15 mice were usod for each dose. Values in parenthesis indicate the 95 %
conficicnce range.
Injection site EDso values MRP/FEN
  ratio
Agonist
FEN MRP
s.c.
i.c.v.
i't'
O.035 ymol/kg
 (O.Oas-O.e49)
O.10 nmoVmouse
  (G.04-O.es)
O.11 nmoYmouse
  (O.05-O.as)
 2.58 IAmollkg
  (1.37-4.ss)
1.85 rmoVmouse
  (1.17-Z92)
O.13 nmoYmouse
  (O.06-O.28)
73.7
18.5
1.2
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Fig. 3 The dose-response curve for antinociceptive effect induced by i.c.y. injection of morphine (A)
or fentanyl (B) in CXBK and C57BL/6J (C57BL) mice. Antinociception was expressed as a
percentage of maximum possible effect (9o Antinociception). Each point represents the mean Å}
S.E.M, of 5-6 mice. "'"pÅq O.OO1, ##pÅq O.Ol and ###pÅq O.OO 1 vs. C57BL mice.
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The displacement of [3H]DAMGO binding
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Fig. 4 Comparison of binding affinities of morphine and fentanyl determined from competitive
displacement binding against [3H]DAMGO in spinal membranes of ICR mice. Competitiye
displacement binding by morphine or fentanyl was performed incubating spinal membranes with 1
nM [3H]DAMGO in the presence of graded concentrations (O.Ol-1oo pM) of unlabeled morphine or
fentanyl. Nonspecific binding was determined using 1 pM DAMGO. For all competitive binding
assays, ICso was determined from the displacement curves. Values in parenthesis indicate the 95 9o
confidence range.
68
(A)
T
ts
fl
8
ts
bD
MOR(34S bp)
GAPDH(427 bp)
120
110
100
90
80
70
60
so
ng
30
20
 10
 o
**
C57BL16 CXBK
(B)
MOR-IB(S47 bp)
GAPDI-I
(427 bp)
  120
  110
  lOO
   90
   80
6 7og
8 6o
ts so
be
   40
   30
   20
   10
    o
CXBK
(C)
6
ts
"8
ts
*
MOR.1(245 bp)
GAPDII
(427 bp)
120
110
1OO
90
80
70
60
so
40
30
20
 10
 o
C57BL/6 C57BL16 CXBK
Fig. 5 Reduced expression of MOR-IB mRNA in the spinal cord of CXBK mice. Upper:
Representative RT-PCR for overall MORs (A), MOR-IB (B) and MOR-1 (C) mRNAs in the spinal
cord obtained from C57BL16J and CXBK mice. Lower: Semi-quantitation of the intensity of the
each band. The sample mixture was subjected to 29o agarose gel electrophoresis with the indicated
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Fig. 6 (A) and (B) The antinociceptive effect induced by i.t. injection of morphine or fentanyl in
CXBK and C57BL16J mice. The mouse tail-flick assay was performed at 10 or 5 min after i.t.
injection of morphne or fentanyl. Each point represents the mean with S.E.M. of 4-6 mice for each
group. Values in parenthesis indicate the 959o confidence range. (C) and (D) Effect of morphine or
fetanyl on the binding of [35S]GTPyS to membranes of the spinal cord obtained from C57BL16J and
CXBK mice. Membranes were incubated with 50 pM [35S]GTPyS and 30 ptM GDP with or without
different concentrations (O.1 nM-10 pM) of morphine or fentanyl. The data are expressed as a
percentage of basal [35S]GTPyS binding measured in the presence of GDP and absence of agonist.
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Discussion
   In the present study using the mouse tail-flick test, both morphine and fentanyl
produced dose-dependent antinociceptive effects- after s.c., i.c.v. or i.t. administration.
These effects were significantly attenuated by pretreatment with the MOR antagonist 6--
FNA. The DOR antagonist NTI and KOR antagonist nor-BNI had no effects on
antinociception induced by s.c. injection of morphine or fentanyl, whereas the dose of
NTI or nor-BNI was sufficiently effective to inhibit the antinociceptiye effect produced
by DPDPE or U-50,488H. These findings indicate that either morphine or fentanyl
induce antinociceptive effect via supraspinal and spinal MORs.
    I determined the EDso values for s.c., i.c.v. or i.t. injection of morphine- and
fentanyl-induced antinociception in ddY mice. It is noteworthy that the MRPIFEN
ratio for s.c. administration was much higher than that for i.t. and i.c.v. injections,
These differences may result from their pharmacokinetic profiles. This notion can be
supported by the finding that unlike morphine, fentanyl has a lipid-soluble profile and
thus easily diffuses into the brain across the blood-brain barrier. This may be the
major reason why s.c. injection of fentanyl can produce more potent antinociception
than that of morphine. Furthermore, the present data provide further evidence for the
usefulness of peripheral treatment with fentanyl as therapeutic strategies for the control
of pain.
   Next, I investigated the specific involvement of the opioid receptor types and MOR
subtypes in analgesic properties of morphine and fentanyl. As mentioned in Chapter 2,
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I demonstrated that CXBK strain can be classified as MOR-IB-knockdown mice, and
that MOR-IB plays an important role in supraspinal antinociception of the endogenous
MOR agonist endomorphin-1. In the present study, both morphine and fentanyl when
given i.c.v. induced antinociception in outbred ddY mice and inbred C57BL16J mice.
Conversely, antinociceptive activity induced by i.c.v. administration of both morphine
and fentanyl was much lower in CXBK mice, being in good agreement with the finding
of endomorphin-1 in Chapter 2. These findings indicate that antinociceptiye effects of
i.c.v.-administered morphine and fentanyl are, at least in part, mediated through MOR-
IB at the supraspinal site.
    In order to further understand the roles of the opioid receptor types and MOR
subtypes in the antinociceptive effects of morphine and fentanyl at spinal levels, I
performed the competitive displacement binding study using [3HIDAMGO. In the
present study, no significant difference in the binding affinity to MORs in the mouse
spinal cord was noted between morphine and fentanyl, pointing out the possibility that
both morphine and fentanyl basically act on spinal MORs in the same manner. Next, I
investigated the antinociceptive effects induced by i.t. administration of morphine or
fentanyl in CXBK mice. In the present study, I demonstrated that CXBK mice display
a significant reduction in the expression of MOR-IB mRNA in the spinal cord
compared to that in their progenitor C57BL/6J mice. Furthermore, the expression of
overall MOR mRNA is decreased in the spinal cord of CXBK mice. These findings
are consistent with the previous report that the level of MOR mRNA in the brain of
CXBK mice is reduced to approximately 609o of their progenitor mice 52). In contrast,
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the expression level of MOR-1 mRNA in the brain of CXBK mice was similar to that
found in C57BL16J mice. Thus, the present findings indicate a specific loss of MOR-
IB mRNA expression in the spinal cord, as well as brain, of this strain. Under these
conditions, it is of interest to note that either the spinal antinociceptive effect induced by
morphine or fentanyl in C57BL/6J mice was significantly decreased in CXBK mice
with the same degree. In addition, there was no significant difference between
morphine and fentanyl on G-protein activation in MOR-IB knockdown CXBK mice.
Taken together, the present findings suggest that MOR-IB may, at least in part, play a
potential role in both morphine- and fentanyl-mediated spinal antinociception.
    The large body of evidence suggests that the binding of structurally distinct ligands
to GPCR including opioid receptors leads to the multiple changes of receptor
conformation, which could trigger distinct signal pathway. 8'+83) Considering these
findjngs, although I could not provide evidence for the essential difference of
mechanisms underlying spinal antinociceptive effects between morphine and fentanyl in
the present study, there is a possibility that morphine and fentanyl shows the essential
difference in the binding site of each agonist in MOR or agonist-MOR binding form,
which could lead to the distinct change in MOR conformation and downstream
signaling machinery. Alternatively, there is another possibility that morphine and
fentanyl reveal the distinct reactivity to MOR subtypes excluding MOR-IB in the
mouse spinal cord. To further understand the differences in molecular mechanisms
underlying the antinociceptive effects between morphine and fentanyl, more
experiments are needed to perform.
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    In conclusion, the present data provide the evidence that a lack of MOR-IB
expression may, at least in part, contribute to the reduced sensitivity to morphine and
fentanyl at either the supraspinal or spinal site of CXBK mice. Furthermore, MOR--IB
may play a potential role in the MOR-mediated antinociception at both the supraspinal
and spinal sites.
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General conclusion
The above findings lead to the following conclusions:
In Chapter 1:
   The anti-hyperalgesic effect induced by fentanyl in CFA-pretreated mice was
rapidly disappeared during the consecutive administration of fentanyl, whereas
morphine preserved its potency of anti-hyperalgesic effect. In addition, repeated
treatment with fentanyl, but not morphine, resulted in the increase in levels of p-MOR
associated with the enhanced inactivation of PP2A and the reduction in Rab4-dependent
MOR resensitization. These findings point out the possibility that chronic treatment
with fentanyl may cause the different modulation from chronic treatment with morphine
on either the internalization or resensitization of MORs in the spinal cord under the
pain-like state. The present data provide first evidence for the mechanism underlying
the development of tolerance to fentanyl-induced anti-hyperalgesic effect under the
chronic pain.
In Chapter 2:
   Here I found for the first time that CXBK recombinant-inbred mice display a
significant reduction in the expression of MOR-IB mRNA in the brain as compared to
that in their progenitor C57BL/6J mice. Furthermore, relatively lower levels of MOR-
IB-IR were detected in the PA6 of CXBK mice than that observed in C57BL16J mice.
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Under these conditions, I found that the increased level of [35SIGTPyS bindings to
whole brain membranes induced by a selective MOR agonist endomorphin-1 was
significantly decreased in CXBK mice, indicating that CXBK strain can be classified as
MOR-IB-knockdown mice. In addition, the i.c.v. pretreatment with AS-ODN to exon
5 of MOR gene produced a significant reduction in the i.c.v.-administered
endomorphin-1-induced antinociceptive effect, being in good agreement with the
findings in CXBK mice. The present data provide the first evidence that a lack of
MOR-IB expression may, at least in part, contribute to the reduced sensitivity to MOR
agonists in CXBK mice, and that MOR-IB may play a critical role in the MOR-
mediated supraspinal antinociception.
In Chapter 3:
   In the present study using the mouse tail-flick test, the antinociceptive effects
induced by s.c., i.c.v. or i.t. administration of either morphine or fentanyl were
significantly attenuated by pretreatment with MOR antagonist P-FNA, confirming that
either morphine or fentanyl induce antinociceptive effect via supraspinal and spinal
MORs. Furthermore, CXBK mice exhibited a weak antinociception induced by i.c.y.
administration of both morphine and fentanyl as compared to that in C57BL/6J mice at
the doses used in the present study. In competitive displacement binding study using
[3H]DAMGO, no significant difference in the binding affinity to MORs in the mouse
spinal cord was noted between morphine and fentanyl. Interestingly, RT-PCT assay
showed that a specific loss of MOR-IB mRNA expression in the spinal cord of CXBK
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mice. Under these conditions, it should be noted that either the spinal antinociceptive
effect and G-protein activation induced by morphine or fentanyl in C57BU6J mice were
significantly decreased in CXBK mice with the same degree. Taken together, the
present findings suggest that MOR-IB may, at least in part, play an important role in
both morphine- and fentanyl-mediated supraspinal and spinal antinociception.
Working hypothesis
   Based on the findings noted, I try to describe my hypothesis concerning the change
in the spinal function following chronic morphine treatment (See Fig. A). Repeated
treatment with fentanyl, but not morphine, resulted in the increase in levels of p-MOR
associated with the enhanced inactivation of PP2A and the reduction in Rab4-dependent
MOR resensitization. However, I could not detect the essential difference of
mechanisms underlying spinal antinociceptive effects between morphine and fentanyl in
the present study. It seems likely that these differences in tolerance to anti-
hyperalgesic effects between chronic treatment with morphine and fentanyl under the
pain-like state may result from the distinct reactivity between morphine and fentanyl to
MOR subtypes excluding MOR-IB in the mouse spinal cord. Alternatively, the
different pharmacologjcal profile between morphine and fentanyl observed in the
present study may reflect the essential difference of each MOR agonist in the the
binding site of each agonist in MOR or agonist-MOR binding form, leading to the
conformational changes in MOR at the spinal site. Although further experiments are
needed to perform, the present findings proyide the first evideRce for the molecular
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mechanism underlying the development of
hyperalgesic effect under the chronic pain.
tolerance to fentanyl-induced anti-
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Fig. A (a) Schematic models of the p-opioid receptor (MOR) tumover fo]lowing chronic treatment with
morphine or fentanyl. Fentanyl induces internalization ot" MORs, In contrast, morphine does not promote
detectable internalization of MORs after repeated treatment, a]though it is well established that morphine induces
the phosphorylation of MORs, (b) Schematic models of changes in the MOR turnover during a neuropathic
pain. It has been considered that the release of endogenous MOR peptides such as l3-endorphin and
endomorphins is increased in the spinal cord during a neuropathic pain, It is reported that endogenous opioid
peptides induce internalization of MORs (see jn the reference 56), (c ) Schematic models of the difference of
mechanisrns underlying tolerance to anti-hyperalgesic effects between chronic treatment with morphine and
fentanyl under the pain-like state in the mouse spinal cord, See the detail in "Working hypothesis",
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